Streptococcal B vaccine conjugate - GlaxoSmithKline

Drug Profile

Streptococcal B vaccine conjugate - GlaxoSmithKline

Alternative Names: CRM-glycoconjugate GBS vaccine; GBS maternal vaccine; GBS Trivalent Vaccine; GBS vaccine; GBS vaccine - GlaxoSmithKline; GBS vaccine - Intercell; GBS vaccine - Valneva; Group B Streptococcus vaccine - Intercell; Group B Streptococcus vaccine - Valneva; Trivalent PG vaccine - GlaxoSmithKline

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercell
  • Developer GlaxoSmithKline
  • Class Glycoconjugates; Polysaccharides; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Streptococcal infections

Most Recent Events

  • 10 Dec 2016 GlaxoSmithKline completes a phase-II clinical trials in Streptococcal infections (Prevention, In volunteers, In adults) in Belgium (IM) (NCT02690181)
  • 01 Mar 2016 Phase-II clinical trials in Streptococcal infections (Prevention, In volunteers, In adults) in Belgium (IM) (NCT02690181)
  • 01 Mar 2016 Novartis Vaccines completes a phase II trial in Streptococcal infections (Prevention, In neonates, In infants) in USA (NCT02046148)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top